Skip to main content

Genethon to Use Hybrigenics Y2H Platform, Software for Muscular Dystrophy Research

NEW YORK, Dec. 21 (GenomeWeb News) - Genethon, a research center funded by the French Muscular Dystrophy Association, will use Hybrigenics' yeast two-hybrid screening platform to study muscle cell proteins, Hybrigenics said today.

 

Genethon conducted a pilot screening study with Hybrigenics in 2004 and 2005 that identified several proteins involved in muscular dystrophies, the company said. Genethon will now use the screening platform along with Hybrigenics' protein interaction mapping software, PIMRider, to discover interactions between the proteins.

 

Hybrigenics said that Genethon will use the technology to map "genome-wide interactomes" to study protein mechanisms. Under the agreement, all data will belong to Genethon.

 

France's Muscular Dystrophy Association provided €894,000, or $1.2 million, in funding to support the project.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.